| Development code number |
Class or application |
Developmental stage (1Q2006) |
| CS-747 (prasugrel) |
Oral antiplatelet agent |
Phase III |
| Colesevelam |
Diabetes (BAS) |
Phase III |
| CS-8663 |
Hypertension |
Phase III |
| CS-011 (rivoglitazone) |
Diabetes (PPAR) |
Phase II-III |
| DJ-927 |
Cancer chemotherapeutic (Taxane) |
Phase II |
| DU-176b |
Anticoagulant.(Factor Xa Inhibitor) |
Phase II |
| CS-3030 |
Anticoagulant.(Factor Xa Inhibitor) |
Phase I |
| DZ-697b |
Novel anti-platelet |
Phase I |
| CS-7017 |
Oncology (PPAR gamma) |
Phase I |
| CS-1008 |
Oncology (DR5) |
Phase I |
| CS-0777 |
Immunosuppressive |
Pre-clinical |
|
|
